Home
Transgene Biotek Ltd PE Ratio

Transgene Biotek Ltd
NSE: TRANSGENEBIOTEK
PE
Key Highlights
- The P/E Ratio of Transgene Biotek Ltd is 0 as of 22 Feb 11:58 AM .
- The P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
- The Latest Trading Price of Transgene Biotek Ltd is ₹ 4.23 as of 21 Feb 15:30 .
- The PE Ratio of Healthcare Industry has changed from 35.5 to 62.3 in 5 years. This represents a CAGR of 11.91%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of Healthcare industry is 62.3. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.
Historical P/E Ratio of Transgene Biotek Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Transgene Biotek Ltd
Company Fundamentals for Transgene Biotek Ltd

Transgene Biotek Ltd
NSE: TRANSGENEBIOTEK
Share Price
Market Price of Transgene Biotek Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 4.23 |
20 Feb 2025 | 4.25 |
19 Feb 2025 | 4.25 |
18 Feb 2025 | 4.06 |
17 Feb 2025 | 4.2 |
14 Feb 2025 | 4.4 |
13 Feb 2025 | 4.31 |
12 Feb 2025 | 4.43 |
11 Feb 2025 | 4.34 |
10 Feb 2025 | 4.47 |
SWOT Analysis Of Transgene Biotek Ltd
BlinkX Score for Transgene Biotek Ltd
Asset Value vs Market Value of Transgene Biotek Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Transgene Biotek Ltd | 32.05 | - |
Max Healthcare Institute Ltd | 98177 | 92.6 |
Apollo Hospitals Enterprise Ltd | 90854 | 69.3 |
Fortis Healthcare Ltd | 46713 | 59.2 |
Global Health Ltd | 33160 | 65.4 |
Syngene International Ltd | 28739 | 60.2 |
Company | |
---|---|
Transgene Biotek Ltd | 32.05 |
Max Healthcare Institute Ltd | 98177 |
Apollo Hospitals Enterprise Ltd | 90854 |
Fortis Healthcare Ltd | 46713 |
Global Health Ltd | 33160 |
Syngene International Ltd | 28739 |
PE Ratio of Transgene Biotek Ltd Explained
₹32.05
Market cap
₹0
Earnings
0.0X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Healthcare Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Transgene Biotek Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Transgene Biotek Ltd
Historical Revenue, EBITDA and Net Profit of Transgene Biotek Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Transgene Biotek Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Transgene Biotek Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Transgene Biotek Ltd
About Transgene Biotek Ltd
- Founded in March, 1990 by Dr. Koteswara Rao, Transgene Biotek Ltd was one of the first Biotechnology companies in India.
- Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
- The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune. Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.
Transgene Biotek Ltd News Hub
Transgene Biotek reports consolidated net profit of Rs 0.20 crore in the June 2024 quarter
Net profit of Transgene Biotek reported to Rs 0.20 crore in the quarter ended June 2024 as against n
Read more
12 Aug 24
Transgene Biotek to announce Quarterly Result
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 12 November 2024 Po
Read more
05 Nov 24
Transgene Biotek reports consolidated net loss of Rs 0.07 crore in the September 2024 quarter
Net Loss of Transgene Biotek reported to Rs 0.07 crore in the quarter ended September 2024 as agains
Read more
12 Nov 24
Transgene Biotek declare Quarterly Result
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 24 January 2025. Po
Read more
17 Jan 25